As a subtype of humanized PM-1 antibody against interleukin-6 receptor (IL-6R), there is provided antibody sub-type (1) whose one heavy chain C terminus consists of Pro-NH2 (447). As another subtype of humanized PM-1 antibody against interleukin-6 receptor (IL-6R), there is provided antibody subtype (2) whose both heavy chain C termini consist of Pro-NH2 (447). Furthermore, there are provided pharmaceutical compositions comprising these.